Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Special Issue: Current evidence and perspectives for hypertension management in Asia
  • Published:

Effect of the interaction between the visceral-to-subcutaneous fat ratio and aldosterone on cardiac function in patients with primary aldosteronism

Hypertension Research volumeĀ 46,Ā pages 1132ā€“1144 (2023)Cite this article

A Comment to this article was published on 01 March 2023

Abstract

Primary aldosteronism is the most frequent secondary hypertensive disease and is characterized by an elevated risk for cardiovascular disease. The current standard treatments are adrenalectomy and/or administration of mineralocorticoid receptor blockers, both of which are effective at ameliorating hypertension via intervention for hyperaldosteronism. However, both of these approaches have side effects and contraindications, and mineralocorticoid receptor blockers also have limited preventive efficacy against cardiovascular events. Recently, in vitro experiments have shown that aldosterone regulation is closely related to abdominal fat accumulation and that there is crosstalk between aldosterone and visceral fat tissue accumulation. We previously reported that this interaction was clinically significant in renal dysfunction; however, its effects on the heart remain unclear. Here, we analyzed data from 49 patients with primary aldosteronism and 29 patients with essential hypertension to examine the potential effect of the interaction between the ratio of visceral-to-subcutaneous fat tissue volume and the plasma aldosterone concentration on echocardiographic indices, including the tissue Doppler-derived E/eā€™ ratio. A significant interaction was found in patients with primary aldosteronism (pā€‰<ā€‰0.05), indicating that patients with the combination of a high plasma aldosterone concentration and high visceral-to-subcutaneous fat ratio show an increased E/eā€™ ratio, which is a well-known risk factor for future cardiovascular events. Our results confirm the clinical importance of the interaction between aldosterone and abdominal fat tissue, suggesting that an improvement in the visceral-to-subcutaneous fat ratio may be synergistically and complementarily effective in reducing the elevated risk of cardiovascular disease in patients with primary aldosteronism when combined with conventional therapies for reducing aldosterone activity.

A significant effect of the interaction between plasma aldosterone concentration and the visceral-to-subcutaneous fat ratio on the tissue Doppler-derived E/e' ratio in patients with primary aldosteronism.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Conn JW, Knopf RF, Nesbit RM. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg. 1964;107:159ā€“72.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  2. Nishikawa T, Omura M, Satoh F, Shibata H, Takahashi K, Tamura N, et al. Guidelines for the diagnosis and treatment of primary aldosteronism -The Japan Endocrine Society 2009. Endocr J. 2011;advpub:1108040599-1108040599.

  3. Naruse M, Katabami T, Shibata H, Sone M, Takahashi K, Tanabe A, et al. Japan Endocrine society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021. Endocr J. 2022;69:327ā€“59.

    ArticleĀ  PubMedĀ  Google ScholarĀ 

  4. Rossi GP, Bello VD, Ganzaroli C, Sacchetto A, Cesari M, Bertini A, et al. Excess idosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension. 2002;40:23ā€“7.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  5. Neves MF, Cunha AR, Cunha MR, Gismondi RA, Oigman W. The role of renin-angiotensin-aldosterone system and its new components in arterial stiffness and vascular aging. High Blood Press Cardiovasc Prev. 2018;25:137ā€“45.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  6. Wu X, Yu J, Tian H. Cardiovascular risk in primary aldosteronism: A systematic review and meta-analysis. Med (Baltim). 2019;98:e15985.

    ArticleĀ  Google ScholarĀ 

  7. Chang Y-Y, Liao C-W, Tsai C-H, Chen C-W, Pan C-T, Chen Z-W, et al. Left ventricular dysfunction in patients with primary aldosteronism: a propensity score-matching follow-up study with tissue doppler imaging. J Am Heart Assoc. 2019;8:e013263ā€“e013263.

    ArticleĀ  PubMedĀ  PubMed CentralĀ  Google ScholarĀ 

  8. Chen Y-L, Xu T-Y, Xu J-Z, Zhu L-M, Li Y, Wang J-G. A non-invasive left ventricular pressure-strain loop study on myocardial work in primary aldosteronism. Hypertens Res. 2021;44:1462ā€“70-1462.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  9. Chen Y-L, Xu T-Y, Xu J-Z, Zhu L-M, Li Y, Wang J-G. A prospective comparative study on cardiac alterations after surgery and drug treatment of primary aldosteronism. Front Endocrinol (Lausanne). 2021;12:770711ā€“770711.

    ArticleĀ  PubMedĀ  Google ScholarĀ 

  10. Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018;6:51ā€“9.

    ArticleĀ  PubMedĀ  Google ScholarĀ 

  11. Briet M, Schiffrin EL. The role of aldosterone in the metabolic syndrome. Curr Hypertens Rep. 2011;13:163ā€“72.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  12. Ingelsson E, Pencina MJ, Tofler GH, Benjamin EJ, Lanier KJ, Jacques PF, et al. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the framingham offspring study. Circulation. 2007;116:984ā€“92.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  13. Hanslik G, Wallaschofski H, Dietz A, Riester A, Reincke M, Allolio B, et al. Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Connā€™s Registry. Eur J Endocrinol. 2015;173:665ā€“75.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  14. Shibayama Y, Wada N, Baba S, Miyano Y, Obara S, Iwasaki R, et al. Relationship between visceral fat and plasma aldosterone concentration in patients with primary aldosteronism. J Endocr Soc. 2018;2:1236ā€“45.

    ArticleĀ  CASĀ  PubMedĀ  PubMed CentralĀ  Google ScholarĀ 

  15. Werner N, Nickenig G. From fat fighter to risk factor: the zigzag trek of leptin. Arterioscler Thromb Vasc Biol. 2004;24:7ā€“9.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  16. Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K, et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension. 2004;43:1318ā€“23.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  17. Tan KC, Xu A, Chow WS, Lam MC, Ai VH, Tam SC, et al. Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab. 2004;89:765ā€“9.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  18. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes. 2007;56:1010ā€“3.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  19. Lemieux I, Pascot A, Prudā€™homme D, Almeras N, Bogaty P, Nadeau A, et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol. 2001;21:961ā€“7.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  20. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112:1796ā€“808.

    ArticleĀ  CASĀ  PubMedĀ  PubMed CentralĀ  Google ScholarĀ 

  21. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology. 2004;145:2273ā€“82.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  22. Kataoka H, Mochizuki T, Iwadoh K, Ushio Y, Kawachi K, Watanabe S, et al. Visceral to subcutaneous fat ratio as an indicator of a >/=30% eGFR decline in chronic kidney disease. PLoS One. 2020;15:e0241626.

    ArticleĀ  CASĀ  PubMedĀ  PubMed CentralĀ  Google ScholarĀ 

  23. Silveira EA, Kliemann N, Noll M, Sarrafzadegan N, de Oliveira C. Visceral obesity and incident cancer and cardiovascular disease: An integrative review of the epidemiological evidence. Obes Rev. 2021;22:e13088.

    ArticleĀ  PubMedĀ  Google ScholarĀ 

  24. Lind L, Michaelsson K, Sƶderberg S, Larsson A, Johansson L, Kullberg J, et al. On the association between body fat and left ventricular mass. J Hypertens. 2019;37:1699ā€“704.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  25. Di Chiara T, Licata A, Argano C, Duro G, Corrao S, Scaglione R. Plasma adiponectin: a contributing factor for cardiac changes in visceral obesity-associated hypertension. Blood Press. 2014;23:147ā€“53.

    ArticleĀ  PubMedĀ  Google ScholarĀ 

  26. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, Willenberg HS, Barthel A, et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci USA. 2003;100:14211ā€“6.

    ArticleĀ  CASĀ  PubMedĀ  PubMed CentralĀ  Google ScholarĀ 

  27. Huby AC, Antonova G, Groenendyk J, Gomez-Sanchez CE, Bollag WB, Filosa JA, et al. Adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis. Circulation. 2015;132:2134ā€“45.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  28. Guo C, Ricchiuti V, Lian BQ, Yao TM, Coutinho P, Romero JR, et al. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation. 2008;117:2253ā€“61.

    ArticleĀ  CASĀ  PubMedĀ  PubMed CentralĀ  Google ScholarĀ 

  29. Kraus D, Jager J, Meier B, Fasshauer M, Klein J. Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes. Horm Metab Res. 2005;37:455ā€“9.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  30. Jia G, Aroor AR, Sowers JR. The role of mineralocorticoid receptor signaling in the cross-talk between adipose tissue and the vascular wall. Cardiovasc Res. 2017;113:1055ā€“63.

    ArticleĀ  CASĀ  PubMedĀ  PubMed CentralĀ  Google ScholarĀ 

  31. Haze T, Hatakeyama M, Komiya S, Kawano R, Ohki Y, Suzuki S, et al. Association of the ratio of visceral-to-subcutaneous fat volume with renal function among patients with primary aldosteronism. Hypertens Res. 2021;44:1341ā€“51.

    ArticleĀ  CASĀ  PubMedĀ  PubMed CentralĀ  Google ScholarĀ 

  32. Nishikawa T, Omura M, Satoh F, Shibata H, Takahashi K, Tamura N, et al. Guidelines for the diagnosis and treatment of primary aldosteronism-the Japan Endocrine Society 2009. Endocr J. 2011;58:711ā€“21.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  33. Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019;42:1235ā€“481.

    ArticleĀ  PubMedĀ  Google ScholarĀ 

  34. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for Chamber Quantification: A Report from the American Society of Echocardiographyā€™s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440ā€“63.

    ArticleĀ  PubMedĀ  Google ScholarĀ 

  35. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16:233ā€“71.

    ArticleĀ  PubMedĀ  Google ScholarĀ 

  36. Fuchs A, KĆ¼hl JT, Sigvardsen PE, Knudsen AD, Nilsson EJP, Stisen ZR, et al. Arterial hypertension and morphologic abnormalities of cardiac chambers: results from the Copenhagen General Population Study. J Hypertens. 2021;39:703ā€“10.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  37. Galderisi M, Cosyns B, Edvardsen T, Cardim N, Delgado V, Di Salvo G, et al. Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2017;18:1301ā€“10.

    ArticleĀ  PubMedĀ  Google ScholarĀ 

  38. Schussheim AE, Devereux RB, de Simone G, Borer JS, Herrold EM, Laragh JH. Usefulness of subnormal midwall fractional shortening in predicting left ventricular exercise dysfunction in asymptomatic patients with systemic hypertension. Am J Card. 1997;79:1070ā€“4.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  39. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29:277ā€“314.

    ArticleĀ  PubMedĀ  Google ScholarĀ 

  40. Tei C, Ling LH, Hodge DO, Bailey KR, Oh JK, Rodeheffer RJ, et al. New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function-a study in normals and dilated cardiomyopathy. J Cardiol. 1995;26:357ā€“66.

    CASĀ  PubMedĀ  Google ScholarĀ 

  41. Yasuoka K, Harada K, Toyono M, Tamura M, Yamamoto F. Tei index determined by tissue doppler imaging in patients with pulmonary regurgitation after repair of tetralogy of fallot. Pediatr Cardiol. 2004;25:131ā€“6.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  42. Mansour H, Nassar AI, Abdel Rehim WA, Roushdy AM, Abobakr M, Zaki HM, et al. Can Tei index predict high syntax score in patients with chronic coronary syndrome and normal left ventricular systolic function? J Cardiovasc Echogr. 2021;31:11ā€“6.

    ArticleĀ  PubMedĀ  PubMed CentralĀ  Google ScholarĀ 

  43. Rossi GP, Auchus RJ, Brown M, Lenders JWM, Naruse M, Plouin PF, et al. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. Hypertension. 2014;63:151ā€“60.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  44. Kempers MJE, Lenders JWM, van Outheusden L, van der Wilt GJ, Schultze Kool LJ, Hermus ARMM, et al. Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med. 2009;151:329ā€“37.

    ArticleĀ  PubMedĀ  Google ScholarĀ 

  45. Monticone S, Dā€™Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6:41ā€“50.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  46. Parra RamĆ­rez P, Rojas-Marcos PM, Paja Fano M, GonzĆ”lez Boillos M, Pascual-Corrales E, GarcĆ­a-Cano A, et al. Differences in the presentation and evolution of primary aldosteronism in elderly (ā‰„65 years) and young patients (<65 years). Endocr Connect. 2022;11:e220169.

    ArticleĀ  PubMedĀ  PubMed CentralĀ  Google ScholarĀ 

  47. Haze T, Hirawa N, Yano Y, Tamura K, Kurihara I, Kobayashi H, et al. Association of aldosterone and blood pressure with the risk for cardiovascular events after treatments in primary aldosteronism. Atherosclerosis 2021;324:84ā€“90.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  48. Haze T, Yano Y, Hatano Y, Tamura K, Kurihara I, Kobayashi H, et al. Association of achieved blood pressure after treatment for primary aldosteronism with long-term kidney function. J Hum Hypertens. 2021.).

  49. Sharp ASP, Tapp RJ, Thom SAM, Francis DP, Hughes AD, Stanton AV, et al. Tissue Doppler E/Eā€² ratio is a powerful predictor of primary cardiac events in a hypertensive population: an ASCOT substudy. Eur Heart J. 2009;31:747ā€“52.

    ArticleĀ  PubMedĀ  Google ScholarĀ 

  50. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006;444:881ā€“7.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  51. Dā€™Marco L, Puchades MJ, Gorriz JL, Romero-Parra M, Lima-Martinez M, Soto C, et al. Epicardial adipose tissue, adiponectin and leptin: a potential source of cardiovascular risk in chronic kidney disease. Int J Mol Sci. 2020;21:978.

    ArticleĀ  PubMedĀ  PubMed CentralĀ  Google ScholarĀ 

  52. Otero M, Lago R, Lago F, Casanueva FF, Dieguez C, GĆ³mez-Reino JJ, et al. Leptin, from fat to inflammation: old questions and new insights. FEBS Lett. 2005;579:295ā€“301.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  53. Poetsch MS, Strano A, Guan K. Role of leptin in cardiovascular diseases. Front Endocrinol (Lausanne). 2020;11:354.

    ArticleĀ  PubMedĀ  Google ScholarĀ 

  54. GutiĆ©rrez-Tenorio J, MarĆ­n-Royo G, MartĆ­nez-MartĆ­nez E, MartĆ­n R, Miana M, LĆ³pez-AndrĆ©s N, et al. The role of oxidative stress in the crosstalk between leptin and mineralocorticoid receptor in the cardiac fibrosis associated with obesity. Sci Rep. 2017;7:16802.

    ArticleĀ  PubMedĀ  PubMed CentralĀ  Google ScholarĀ 

  55. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79ā€“83.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  56. Kuk JL, Katzmarzyk PT, Nichaman MZ, Church TS, Blair SN, Ross R. Visceral fat is an independent predictor of all-cause mortality in men. Obes (Silver Spring). 2006;14:336ā€“41.

    ArticleĀ  Google ScholarĀ 

  57. Fontes-Carvalho R, Fontes-Oliveira M, Sampaio F, Mancio J, Bettencourt N, Teixeira M, et al. Influence of epicardial and visceral fat on left ventricular diastolic and systolic functions in patients after myocardial infarction. Am J Cardiol. 2014;114:1663ā€“9.

    ArticleĀ  PubMedĀ  Google ScholarĀ 

  58. Capoulade R, Larose E, Mathieu P, Clavel M-A, Dahou A, Arsenault M, et al. Visceral adiposity and left ventricular mass and function in patients with aortic stenosis: the PROGRESSA study. Can J Cardiol. 2014;30:1080ā€“7.

    ArticleĀ  PubMedĀ  Google ScholarĀ 

  59. Caprio M, Antelmi A, Chetrite G, Muscat A, Mammi C, Marzolla V, et al. Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome. Endocrinology. 2011;152:113ā€“25.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  60. Rocchini AP, Moorehead C, DeRemer S, Goodfriend TL, Ball DL. Hyperinsulinemia and the aldosterone and pressor responses to angiotensin II. Hypertension. 1990;15:861ā€“6.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  61. Petrasek D, Jensen G, Tuck M, Stern N. In vitro effects of insulin on aldosterone production in rat zona glomerulosa cells. Life Sci. 1992;50:1781ā€“7.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  62. Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev. 2010;11:11ā€“8.

    ArticleĀ  PubMedĀ  Google ScholarĀ 

  63. Ghantous CM, Azrak Z, Hanache S, Abou-Kheir W, Zeidan A. Differential role of leptin and adiponectin in cardiovascular system. Int J Endocrinol. 2015;2015:534320.

    ArticleĀ  CASĀ  PubMedĀ  PubMed CentralĀ  Google ScholarĀ 

  64. Cuspidi C, Tadic M, Sala C, Quarti-Trevano F, Gherbesi E, Mancia G, et al. Regression of left ventricular hypertrophy in primary aldosteronism after adrenalectomy: a meta-analysis of echocardiographic studies. J Hypertens. 2021;39:775ā€“83.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  65. Riggs K, Ali H, Taegtmeyer H, Gutierrez AD. The use of SGLT-2 inhibitors in type 2 diabetes and heart failure. Metab Syndr Relat Disord. 2015;13:292ā€“7.

    ArticleĀ  CASĀ  PubMedĀ  PubMed CentralĀ  Google ScholarĀ 

  66. Itcho K, Oki K, Ohno H, Yoneda M. Update on genetics of primary aldosteronism. Biomedicines 2021;9:409.

    ArticleĀ  CASĀ  PubMedĀ  PubMed CentralĀ  Google ScholarĀ 

  67. Omata K, Satoh F, Morimoto R, Ito S, Yamazaki Y, Nakamura Y, et al. Cellular and genetic causes of idiopathic hyperaldosteronism. Hypertension 2018;72:874ā€“80.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  68. KƤyser SC, Dekkers T, Groenewoud HJ, van der Wilt GJ, Carel Bakx J, van der Wel MC, et al. Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis. J Clin Endocrinol Metab. 2016;101:2826ā€“35.

    ArticleĀ  PubMedĀ  Google ScholarĀ 

  69. Ranasinghe P, Mathangasinghe Y, Jayawardena R, Hills AP, Misra A. Prevalence and trends of metabolic syndrome among adults in the asia-pacific region: a systematic review. BMC Public Health. 2017;17:101.

    ArticleĀ  CASĀ  PubMedĀ  PubMed CentralĀ  Google ScholarĀ 

  70. Alberti KGMM, Zimmet P, Shaw J. Metabolic syndromeā€”a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23:469ā€“80.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

Download references

Acknowledgements

This study was supported by a basic research grant from Yokohama City University.

Author information

Authors and Affiliations

  1. Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan

    Tatsuya Haze,Ā Moe Ozawa,Ā Rina Kawano,Ā Aiko HarunaĀ &Ā Kouichi Tamura

  2. Department of Nephrology and Hypertension, Yokohama City University Medical Center, Yokohama, Japan

    Tatsuya Haze,Ā Moe Ozawa,Ā Rina Kawano,Ā Aiko Haruna,Ā Yuki Ohki,Ā Shota Suzuki,Ā Akira Fujiwara,Ā Sanae SakaĀ &Ā Nobuhito Hirawa

  3. YCU Center for Novel and Exploratory Clinical Trials (Y-NEXT), Yokohama City University Hospital, Yokohama, Japan

    Tatsuya HazeĀ &Ā Yusuke Kobayashi

Authors
  1. Tatsuya Haze
    View author publications

    You can also search for this author in PubMedĀ Google Scholar

  2. Moe Ozawa
    View author publications

    You can also search for this author in PubMedĀ Google Scholar

  3. Rina Kawano
    View author publications

    You can also search for this author in PubMedĀ Google Scholar

  4. Aiko Haruna
    View author publications

    You can also search for this author in PubMedĀ Google Scholar

  5. Yuki Ohki
    View author publications

    You can also search for this author in PubMedĀ Google Scholar

  6. Shota Suzuki
    View author publications

    You can also search for this author in PubMedĀ Google Scholar

  7. Yusuke Kobayashi
    View author publications

    You can also search for this author in PubMedĀ Google Scholar

  8. Akira Fujiwara
    View author publications

    You can also search for this author in PubMedĀ Google Scholar

  9. Sanae Saka
    View author publications

    You can also search for this author in PubMedĀ Google Scholar

  10. Kouichi Tamura
    View author publications

    You can also search for this author in PubMedĀ Google Scholar

  11. Nobuhito Hirawa
    View author publications

    You can also search for this author in PubMedĀ Google Scholar

Corresponding author

Correspondence to Tatsuya Haze.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisherā€™s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Haze, T., Ozawa, M., Kawano, R. et al. Effect of the interaction between the visceral-to-subcutaneous fat ratio and aldosterone on cardiac function in patients with primary aldosteronism. Hypertens Res 46, 1132ā€“1144 (2023). https://doi.org/10.1038/s41440-023-01170-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41440-023-01170-9

Keywords

This article is cited by

Search

Advanced search

Quick links